Your browser doesn't support javascript.
Evolving biothreat of variant SARS-CoV-2 - molecular properties, virulence and epidemiology.
Kannan, S; Shaik Syed Ali, P; Sheeza, A.
  • Kannan S; School of Medicine, The Maldives National University Male, Maldives. Kannan.subbaram@mnu.edu.mv.
Eur Rev Med Pharmacol Sci ; 25(12): 4405-4412, 2021 Jun.
Article in English | MEDLINE | ID: covidwho-1296351
ABSTRACT
SARS-CoV-2 are enveloped RNA viruses that belong to the family Coronaviridae of genus Beta coronavirus, responsible for the COVID-19 pandemic. The mutation rate is high among RNA viruses and in particular, coronavirus replication is error prone with an estimated mutation rate of 4x10-4 nucleotide substitutions per site per year. Variants of SARS-CoV-2 have been reported from various countries like United Kingdom, South Africa, Denmark, Brazil and India. These variants evolved due to mutations in spike gene of SARS-CoV-2. The most concerning variants are Variant of Concern (VOC) 202012/01 from United Kingdom and B.1.617 variant of India. Other variants include B.1.351 lineages, cluster 5/SARS-CoV-2 variant of Denmark, 501.V2 variant/SARS-CoV-2 variant of South Africa, lineage B.1.1.248/lineage P.1 of Brazil. Mutations in S protein may result in changes in the transmissibility and virulence of SARS-CoV-2. To date, alterations in virulence or pathogenicity have been reported among the variants from many parts of the globe. In our opinion, since the S protein is significantly altered, the suitability of existing vaccine specifically targeting the S protein of SARS-CoV-2 variants is a major concern. The mutations in SARS-CoV-2 are a continuous and evolving process that may result in the transformation of naïve SARS-CoV-2 into totally new subsets of antigenically different SARS-CoV-2 viruses over a period of time.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Mutation Type of study: Observational study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia / Europa Language: English Journal: Eur Rev Med Pharmacol Sci Journal subject: Pharmacology / Toxicology Year: 2021 Document Type: Article Affiliation country: Eurrev_202106_26151

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Main subject: SARS-CoV-2 / COVID-19 / Mutation Type of study: Observational study Topics: Vaccines / Variants Limits: Humans Country/Region as subject: Asia / Europa Language: English Journal: Eur Rev Med Pharmacol Sci Journal subject: Pharmacology / Toxicology Year: 2021 Document Type: Article Affiliation country: Eurrev_202106_26151